Bishal Gyawali, MD, PhD, FASCO, is an Ontario Institute of Cancer Research (OICR) Clinical Investigator, a medical oncologist, and an associate professor in medical oncology and public health sciences and scientist in the Division of Cancer Care and Epidemiology, in Queen’s University, Kingston, Canada. His clinical expertise is across multiple adult solid tumors, with special focus on GI, GU and breast malignancies. 

He sits on the editorial and advisory boards for multiple medicine and oncology journals and has authored or co-authored more than 200 peer-reviewed articles in high-impact journals. Dr. Gyawali’s areas of academic interests include cancer policy, evidence-based oncology, financial toxicities of cancer treatment, clinical trial methods, supportive care, cancer care disparities, and global oncology. He introduced the term “cancer groundshot” advocating for investments in implementation of proven interventions for global cancer control. 

He is the co-leader of the Common Sense Oncology movement, working to ensure cancer research and policy is aligned with the goal of improving outcomes that matter to patients. His interviews and studies have been reported in several influential media such as CNN, NPR, Washington Post, STAT News etc. He is an expert for the WHO Drug Advisory Panel. He is a member of the WHO Essential Medicines List Committee for cancer drugs; ESMO-MCBS, ESMO Communications, and ESMO Public Policy committees, and ASCO-Health Equity and Outcomes Committee.